A new antiplatelet agent is developed for the prevention of recurrence of stroke. In a large randomized clinical trial w
Posted: Mon Apr 11, 2022 7:19 am
A new antiplatelet agent is developed for the prevention of recurrence of stroke. In a large randomized clinical trial with equal numbers of men and women, the rates of stroke are lower in patients receiving the new agent than in patients receiving the standard treatment
Women Men Overall
Standard Treatment
.12 .24
New Antiplatelet Drug .04
.08
.00
A) 8o/o
B) 12o/u
C) 16%
D) 33%
E) 50%
F) 62%
G) 67%
H) 75%
Women Men Overall
Standard Treatment
.12 .24
New Antiplatelet Drug .04
.08
.00
A) 8o/o
B) 12o/u
C) 16%
D) 33%
E) 50%
F) 62%
G) 67%
H) 75%